For Media and Press

Ginolis delivers a production solution for Point-of-Care Cardiac tests

Julkaistu 09.09.2014

Ginolis Ltd delivers an additional point-of-care diagnostic production solution to the Swedish company Fiomi Diagnostics AB (owned by Trinity Biotech PLC, Ireland). The solution is used for dispensing reagents for the point-of-care microfluidic test platform; Meritas.

This new deal includes four new production lines as an expansion to an earlier delivery to Fiomi Diagnostics, which is already using a Ginolis solution. “We have had a fruitful collaboration with Ginolis co-developing the reagent dispensing system for our products that has now led to this multi-system deal to meet our capacity requirements,” Mike Read, Fiomi CEO, says. “Ginolis product platform and know-how have allowed us to tailor a solution to meet our specific needs,” Gerd Rundström (Fiomi COO) states.
“We offer complete, modular manufacturing solutions. They are based on our proprietary product platforms and technologies, including robots and dispensing pumps,” Teijo Fabritius, Ginolis CEO, says.
The total value of the deal is not disclosed.

More information:

Teijo Fabritius
President and CEO, Ginolis Ltd
Phone: +358 (40) 565 1782

About Ginolis
Ginolis Ltd applies state of the art processes and technologies used within the electronics industry for development and manufacturing of MedTech and in vitro diagnostic (IVD) disposable products. The company offers its customers contract development and manufacturing of sophisticated and cost efficient micro-fabricated components, efficient automated assembly of the final products as well as turn-key standardized, modular and space-saving automated production solutions. Ginolis holds several patents and licenses for technologies in dispensing, microfluidics, electronic valves, optics and micro fabrication. Based on these patented technologies, Ginolis is also developing proprietary products that are sold to OEM customers. Ginolis is privately-held, with company roots going back to 2010. It has its headquarters in Oulu, Finland, and a subsidiary in Uppsala, Sweden. Further information can be found at

About Trinity Biotech
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: